Monte Rosa Therapeutics
NASDAQ: GLUEBoston, US · Founded 2019 · Delaware corporation · 227 employees on LinkedIn · 8 known investors
Find your way into Monte Rosa Therapeutics
240 people in our graph share verified history with the Monte Rosa Therapeutics team — schools, employers, funds. One of them is your warm intro.
Walter Kowtoniukunlockedknows Markus Warmuth · together at Third Rock Ventures (overlapped)
knows the team · via Ventus Therapeutics
×10knows the team · via Third Rock Ventures
Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets. The company operates in drug discovery and pharmaceutical development.
Founders & leadership
MW
ST
Sharon TownsoninPh.D., Chief Scientific Officer
JC
John CastleinPh.D., Chief Data and Information Officer
FJ
Filip JankuinM.D., Ph.D., Chief Medical Officer
PN
Phil NicksoninPh.D., J.D., Chief Business and Legal Officer
MW
Magnus WalterinDPhil, Chief Technology Officer
JC
Jennifer ChampouxinChief Operating Officer
AF
Andrew FunderburkinChief Investor Relations and Strategy Officer
Board
AM
BB
AB
KB
Kim BlackwellBoard director
Investors · 8
Aisling Capital✓ verifiedNew York
New Enterprise Associates (NEA)✓ verifiedMenlo Park · $200K – $40Mvia Ali Behbahani · board
Versant Ventures✓ verifiedSan Francisco · $250K – $5M
HBM Partners✓ verifiedZug · $5M – $50M
Amzak HealthNew York
Avoro Capital AdvisorsNew York
GV (Google Ventures)Mountain View · $250K – $50M
Dimension CapitalreportedSan Francisco · $1M – $10M
Reported raises · per SEC filings
Form D private placements$143M disclosed across 2 rounds · 2020–2021
▶$95MraisedMar 2021 · 23 investors · BiotechnologyRule 506(b)
▶$95MraisedMar 2021 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Markus WarmuthExecutive Officer, Director
- Alexander MaywegDirector
- Bradley BolzonDirector
- Ali BehbahaniDirector
- Kim BlackwellDirector
- Drew SchiffDirector
- Chandra P. LeoDirector
- Christine SiuDirector
- Ajim TamboliExecutive Officer
- Offering amount
- $95M
- Amount sold
- $95M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$48MraisedSep 2020 · 17 investors · BiotechnologyRule 506(b)
▶$48MraisedSep 2020 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alexander MaywegDirector
- Bradley BolzonDirector
- Markus WarmuthExecutive Officer, Director
- Ali BehbahaniDirector
- Kim BlackwellDirector
- Offering amount
- $96M
- Amount sold
- $48M
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapBioworld27 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Seeking Alpha19 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with Monte Rosa Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
What Monte Rosa Therapeutics (GLUE)'s Swing From Profit To Deeper Losses Means For Shareholders - Simply Wall St Newssimplywall.st · Aug 2026Frequently asked questions
- What does Monte Rosa Therapeutics do?
- Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets. The company operates in drug discovery and pharmaceutical development.
- Who are Monte Rosa Therapeutics's investors?
- Monte Rosa Therapeutics's investors include Aisling Capital, New Enterprise Associates (NEA), Versant Ventures, HBM Partners, Amzak Health, Avoro Capital Advisors, GV (Google Ventures), Dimension Capital.
- How much funding has Monte Rosa Therapeutics raised?
- Monte Rosa Therapeutics has disclosed $143M raised across 2 rounds.
- Where is Monte Rosa Therapeutics headquartered?
- Monte Rosa Therapeutics is headquartered in Boston, US.